[1] |
Bjornsson E, Angulo P . Non-alcoholic fatty liver disease[J]. Scand J Gastroenterol, 2007,42(9):1023-1030.
|
[2] |
Hubscher S G . Histological assessment of non-alcoholic fatty liver disease[J]. Histopathology, 2006,49(5):450-465.
|
[3] |
Neuschwander-Tetri B A, Clark J M, Bass N M , et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease[J]. Hepatology, 2010,52(3):913-924.
|
[4] |
Chalasani N, Younossi Z, Lavine J E , et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018,67(1):328-357.
|
[5] |
Bellentani S . The epidemiology of non-alcoholic fatty liver disease[J]. Liver Int, 2017,37(S1):81-84.
|
[6] |
Cohen J C, Horton J D, Hobbs H H . Human fatty liver disease: old questions and new insights[J]. Science, 2011,332(37):1519-1523.
|
[7] |
Pessayre D, Fromenty B . NASH: a mitochondrial disease[J]. J Hepatol, 2005,42(6):928-940.
|
[8] |
Koch L . Metabolism: mitochondrial pathways in NAFLD[J]. Nat Rev Endocrinol, 2012,8(3):129.
|
[9] |
Huttenlocher P R, Solitare G B, Adams G . Infantile diffuse cerebral degeneration with hepatic cirrhosis[J]. Arch Neurol, 1976,33(3):186-192.
|
[10] |
Gomez-Zorita S, Fernandez-Quintela A, Macarulla M T , et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress[J]. Br J Nutr, 2012,107(2):202-210.
|
[11] |
Rizki G, Arnaboldi L, Gabrielli B , et al. Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1[J]. J Lipid Res, 2006,47(10):2280-2290.
|
[12] |
Lee G S, Yan J S, Ng R K , et al. Polyunsaturated fat in the methionine-choline-deficient diet influences hepatic inflammation but not hepatocellular injury[J]. J Lipid Res, 2007,48(8):1885-1896.
|
[13] |
Lin J, Wu H, Tarr P T , et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres[J]. Nature, 2002,418(6899):797-801.
|
[14] |
Greenfield V, Cheung O, Sanyal A J . Recent advances in nonalcholic fatty liver disease[J]. Curr Opin Gastroenterol, 2008,24(3):320-327.
|
[15] |
Kashi M R, Torres D M, Harrison S A . Current and emerging therapies in nonalcoholic fatty liver disease[J]. Semin Liver Dis, 2008,28(4):396-406.
|
[16] |
Ioannou G N . The role of cholesterol in the pathogenesis of NASH[J]. Trends Endocrinol Metab, 2016,27(2):84-95.
|
[17] |
Pariente A . Management of non alcoholic fatty liver diseases in adults[J]. Rev Prat, 2012,62(10):1421-1425.
|
[18] |
Ding W X . Role of autophagy in liver physiology and pathophysiology[J]. World J Biol Chem, 2010,1(1):3-12.
|
[19] |
Basaranoglu M, Basaranoglu G, Senturk H . From fatty liver to fibrosis: a tale of "second hit"[J]. World J Gastroenterol, 2013,19(8):1158-1165.
|
[20] |
Cortez-Pinto H, Chatham J, Chacko V P , et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study[J]. JAMA Network, 1999,282(17):1659-1664.
|